Neupogen®(filgrastim)/Neulasta®(pegfilgrastim)
Monitoring Form Outpatient Infusion Center

Age_____ Weight_____(kg) Patient Type (circle): Myelosuppressive Chemotherapy/_____

Place label Here	Dosage Adjustments
	Neupogen doses may be increased in increments of 5 mcg/kg for each chemotherapy cycle, according to the duration and severity of the ANC nadir. **Administer Neupogen daily for up to 2 weeks until the absolute neutrophil count (ANC) has reached 10,000/mm^3 after the expected chemotherapy-induced neutrophil nadir.** **Neupogen therapy should be discontinued if the ANC surpasses 10,000/mm^3 after the expected chemotherapy-induced neutrophil nadir.** **Neulasta: No dosage adjustment is necessary with renal dysfunction** **ANC = $WBC_{k/ul}$ *1000* (Granulocyte as decimal fraction + Bands as decimal fraction)**

Date	Neupogen/Neulasta Drug/Dose/Freq/Route	ANC	WBC*	Platelets*

*CBC and platelet count should be obtained before instituting Neupogen therapy; monitor twice weekly during therapy.

- **Neupogen** <u>should not</u> be administered in the period **24 hours before** or no earlier than **24 hours after** the administration of cytotoxic chemotherapy.
- **Neulasta** <u>should not</u> be used in the period **14 days before to 24 hours after** administration of cytotoxic chemotherapy.
- Doses of Neupogen and Neulasta that increase the ANC beyond 10,000/mm^3 may not result in any additional clinical benefit.
- Leukocytosis (WBC ≥ 100,000/mm^3) has been observed in ~ 2% of patients receiving Neupogen at doses > 5 mcg/kg/day.
- ANC decreases by 50% within 2 days after discontinuing Neupogen; White counts return to the normal range in 4-7 days.

Common Dosing

	Neupogen	Neulasta
Oncology	5 mcg/kg/day Rounded to Nearest Vial Size	6 mg once per chemotherapy cycle